Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07434843 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

PH 2 Pemigatinib in SDH-deficient GIST

Name: PH 2 Pemigatinib in SDH-deficient GIST — clinical trial record (NCT07434843)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: PEMIGIST

StatusRecruiting

PhasePhase 2

SponsorDana-Farber Cancer Institute

Started2026-05-19

View on ClinicalTrials.gov ↗

Amendment history

2026-05-21

Study Status, Contacts/Locations v2

Start dateestimated 2026-04-01→confirmed 2026-05-19

Study sitesdetails revised at 1 of 1 site

2026-04-20

Study Status, Contacts/Locations v1

Recruitment opened

Start date2026-06→2026-04-01

Study sitesdetails revised at 1 of 1 site

2026-02-22

Original filing

Dana-Farber Cancer Institute

287 trials monitored

See 33 trials at risk

The purpose of this study is to determine how effective the drug pemigatinib is as a treatment option for advanced succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors(GIST). This study will also assess the side effects associated with pemigatinib and evaluate its tolerability. The name of the study drug involved in this study is: • Pemigatinib (INCB054828)

Trial Details

NCT Number	NCT07434843
Lead Sponsor	Dana-Farber Cancer Institute Collaborators: Gateway for Cancer Research, Incyte Corporation
Conditions	SDH Gene Mutation, Gastrointestinal Stromal Tumor
Enrollment	24 participants
Start Date	2026-05-19
Primary Completion	2028-10-01 (estimated)
Study Completion	2029-04-01 (estimated)
Updated on ClinicalTrials.gov	2026-05-22